for Health Care Providers
Table 7.Comparison of Sustained Virologic Response Rates (SVR) for Peginterferon Alfa-2b and Interferon Alfa Combination Therapies Given Over 48 Weeks
* Peginterferon alfa-2b 1.5 mcg/kg/wk and ribavirin 800 mg/day. †IFN 3 million U three times weekly plus ribavirin 1,000 or 1,200 mg/day. ‡Compared to interferon alfa plus ribavirin. §Defined as >2 million copies/mL (NGI, sensitivity 100 copies/mL); equivalent to >800,000 IU/mL. ¶Statistical analysis not performed; data from Peg-Intron package insert. ||Defined as ≤2 million copies/mL (NGI, sensitivity 100 copies/mL); equivalent to ≤800,000 IU/mL. | ||
| PATIENT GROUP | SVR | |
|---|---|---|
| Peginterferon alfa-2b plus ribavirin* | Interferon alfa plus ribavirin† | |
| Overall | 54% (p=0.01)‡ | 47% |
| HCV genotype 1 | 42% (p<0.05)‡ | 33% |
| High viral titer§¶ | 30% | 29% |
| Low viral titer|| | Not reported | Not reported |
| HCV genotype 2 or 3 | 82% | 79% |
| HCV genotypes 4-6 | 50% | 38% |
